Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 11
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Cancer Genetics and Cytogenetics 63 (1992), S. 116 
    ISSN: 0165-4608
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Medicine
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 12
    Electronic Resource
    Electronic Resource
    Springer
    Cellular and molecular life sciences 36 (1980), S. 679-680 
    ISSN: 1420-9071
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine
    Notes: Summary The fibrinolytic inhibitor tranexamic acid affects certain experimental tumours; it prolongs survival (Lewis lung adenocarcinoma), decreases tumour weight (C3H breast carcinoma), and inhibits ascitic production (AH 130 rat hepatoma). However, it does not significantly influence DNA-synthesis in cell suspensions prepared from the same tumours.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 13
    ISSN: 1569-8041
    Keywords: cathepsin-D ; nm23 ; ovarian cancer ; prognosis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Different regulators or effectors of the metastatic cascade can be of prognostic and/or predictive significance. Cathepsin-D and nm23 operate at different levels of the metastatic process and have not yet been analyzed in combination in ovarian cancer. Patients and methods: The prevalence of cathepsin-D and nm23 expression was studied with immunohistochemistry in a cohort of 185 previously untreated cases of FIGO stage III ovarian cancer. Correlations with known prognostic factors were examined, and both uni- and multivariate survival analyses were performed. Results: Epithelial cell cathepsin-D expression was found in 58% of cases, stromal cell cathepsin-D expression in 20%, and nm23 expression in 72%. Epithelial cell cathepsin-D expression was positively correlated with better differentiation of the tumor tissue (P = 0.034). No correlation was found between epithelial and stromal cell cathepsin-D expression, but a striking degree of positive correlation was demonstrated between epithelial cell cathepsin-D and nm23 expression (P = 0.005). None of the factors studied was of any value in predicting the response to platinum and anthracyclin combination chemotherapy, as assessed by second look laparotomy. In univariate analysis age, FIGO substage, histological type, differentiation grade, ascites, residual disease and epithelial cathepsin-D were associated with corrected survival. Neither stromal cell cathepsin-D, nor nm23 expression were of prognostic significance. However, in multivariate analysis the combination of epithelial and stromal cell cathepsin-D expression (P = 0.030), residual disease (P = 0.002) and differentiation grade (P = 0.007) were the only remaining independent prognostic factors in this patient group. Conclusions: Our results support a favourable prognostic significance of cathepsin-D expression in advanced ovarian cancer, but underscore the importance of considering both epithelial and stromal cell expression. We could not confirm the prognostic significance of nm23 expression in the present cohort of advanced ovarian cancer patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 14
    Electronic Resource
    Electronic Resource
    Springer
    Annals of oncology 8 (1997), S. 803-806 
    ISSN: 1569-8041
    Keywords: advanced ovarian cancer ; first-line treatment ; paclitaxel
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: We wanted to assess the efficacy and toxicity of paclitaxel(Taxol) in previously untreated patients with advanced ovarian cancer. Nosuch study had been performed at the time of initiation of this study. Patients and methods: The study population in this analysis consisted of35 previously untreated stage III ovarian cancer patients, suboptimallyresected at primary surgery. The initial paclitaxel dose was 175mg/m2 given as a three-hour i.v. infusion every three weeks. Results: A total of 225 paclitaxel courses were given to 35 patients ofwhom 34 were evaluable for clinical response. Nine (26%) patientsobtained a complete response to paclitaxel, ten (29%) a partialresponse, seven (21%) stable disease and eight (24%) hadprogressive disease. Thus, the total response rate to paclitaxel treatmentwas 55% (19 of 34). The median duration of response for the 19responding patients was eight months (range 1–44.5+). The medianduration for nine patients with clinical complete response was 16 months(range 2–44.5+). A second-look laparotomy was performed in 15 patients after six coursesof paclitaxel. Of these, five obtained a histopathologically completeremission, five a partial remission and five stable disease. The fivepatients with pathologically complete remissions are alive with a medianprogressive-free survival of 24.5 months (range 15+–44.5+). The medianprogression-free survival for all patients was 6.1 months (range1–44.5+). Toxicity consisted mainly of neutropenia, easily controlled.Other toxicities were myalgia/arthralgia and peripheral neuropathy. Threepatients experienced a severe anaphylactic reaction during the first course.Conclusion: This study showed that paclitaxel is an effective and safe drugfor first-line treatment of ovarian cancer.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 15
    Electronic Resource
    Electronic Resource
    Springer
    Annals of oncology 10 (1999), S. 3-7 
    ISSN: 1569-8041
    Keywords: secondary interval cytoreductive surgery ; palliative secondary surgery ; second-look surgery
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract During chemotherapy and after relapse several types of operations are used in ovarian cancer: secondary cytoreductive surgery, interval cytoreductive surgery, second-look surgery, and palliative secondary surgery. The role of these operations has been difficult to define because there is considerable variation in the patterns of behaviour of tumours among those with persistent or recurrent disease. The definitions, indications and impact of these procedures are reviewed.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...